HC Wainwright Reiterates Buy Rating on KRYS

HC Wainwright has reiterated its buy rating on KRYS, maintaining a target price of $361. The announcement was made on June 16, 2026, by analyst Joseph Pantginis. Shares of KRYS were trading at $324.75 at the time of the update.

Other Institutional Activity in KRYS

FMR LLC increased its holdings in KRYS by 24,359 shares, bringing its total to 4,373,987 shares valued at approximately $1.13 billion. BlackRock, Inc. also added to its position, with an increase of 2,639 shares, resulting in 3,940,456 shares worth about $1.02 billion. Avoro Capital Advisors LLC held steady with 2,888,888 shares valued at $746.26 million. Meanwhile, Vanguard Portfolio Management LLC entered a new position with 1,456,727 shares worth $376.30 million, and State Street Corp reduced its stake by 27,869 shares, ending with 1,314,434 shares valued at $339.54 million.

Insider Buying and Selling at Krystal Biotech, Inc.

Several insiders at KRYS have been involved in planned sales. On June 4, 2026, Suma Krishnan, President of R&D, and Krish Krishnan, President and CEO, each sold 25,000 shares at an average price of $308.12. Earlier, on May 26, 2026, John Charles Thomas, EVP and General Counsel, sold 642 shares at $302.03. These transactions were conducted under pre-arranged Rule 10b5-1 plans.

Analysts Set New Price Targets

On June 16, 2026, HC Wainwright & Co. maintained its buy rating on KRYS with a price target of $361. Previously, Citigroup maintained a buy rating with a target of $378 on May 5, 2026, while Evercore ISI Group also kept a buy rating with a $300 target on the same date. The consensus among analysts remains positive, with a buy recommendation and a mean price target around these figures.

About KRYS

KRYS is a biotechnology company focused on developing and commercializing innovative gene therapies. The company aims to address unmet medical needs in genetic disorders by leveraging its proprietary technology. Headquartered in the United States, KRYS is led by a team of experienced executives and scientists dedicated to advancing the field of gene therapy.

Bottom Line

HC Wainwright's reiteration of its buy rating on KRYS with a $361 target reflects continued confidence in the company's prospects. Investors keep a close eye on analyst updates and institutional holdings for insights into market sentiment. As always, remember that analyst ratings and institutional filings are backward-looking and do not necessarily reflect current market dynamics.